Skip to content
DataLookout
Menu

NCT07724457

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Start date: Oct 30, 2026 to Jul 27, 2027
    • Eligibility criteria expanded, about 516 words
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description expanded, about 1 word
  2. Notable Start date: Aug 14, 2026 to Oct 30, 2026v3
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression free survival (PFS) (cohort 1) (phase II)
Timeframe: from randomization to the time of documented disease progression or death due to any cause
PFS (cohort 1) (phase III)
Timeframe: At 24 months
PFS (cohort 2) (phase II)
Timeframe: From randomization to the time of documented disease progression or death due to any cause, up to 5 years
PFS (cohort 2) (phase III)
Timeframe: At 24 months
Overall survival (cohort 3)
Timeframe: At 12 months after start of treatment

Secondary (6)

Overall survival (OS)
Event free survival (EFS)
Overall response rate (ORR)
Complete response rate
Transplant or chimeric antigen receptor t-cell (CAR-T) rate (cohort 3)
Show 1 moreShow less
Incidence of adverse events (AEs)

Arms and interventions

Cohort 1 arm 2 RCODOXM/RIVAC or DA-REPOCH and glofitamab)Experimental

See Detailed Description

Cohort 1, arm 1 RCODOXM/RIVAC or DA-REPOCH)Experimental

See Detailed Description.

Cohort 2 arm 3 (DA-REPOCH)Experimental

Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

Cohort 2 arm 4 (DA-REPOCH and glofitamab)Experimental

Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study.

Cohort 3 (RICE and glofitamab)Experimental

See Detailed Description

Procedures: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography

Drugs: Carboplatin, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Methotrexate, Prednisone, Vincristine

Biologicals: Glofitamab, Obinutuzumab, Rituximab, Rituximab and Hyaluronidase Human

Other: Survey Administration

Sites

1 site in 1 country

  • Alliance for Clinical Trials in OncologyChicago, Illinois, United States